• 1
    Bulk S,Visser O,Rozendaal L,Verheijen RH,Meijer CJ. Incidence and survival rate of women with cervical cancer in the greater Amsterdam area. Br J Cancer 2003; 89: 8349.
  • 2
    Davies P,Arbyn M,Dillner J,Kitchener HC,Meijer CJ,Ronco G,Hakama M. A report on the current status of european research on the use of human papillomavirus testing for primary cervical cancer screening. Int J Cancer 2006; 118: 7916.
  • 3
    Peto J,Gilham C,Fletcher O,Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364: 24956.
  • 4
    Cuzick J,Szarewski A,Cubie H,Hulman G,Kitchener H,Luesley D,McGoogan E,Menon U,Terry G,Edwards R,Brooks C,Desai M, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART Study. Lancet 2003; 362: 18716.
  • 5
    Lorincz AT,Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003; 127: 95968.
  • 6
    Moss S,Gray A,Legood R,Vessey M,Patnick J,Kitchener H. Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study. BMJ 2006; 332: 835.
  • 7
    Clifford GM,Smith JS,Aguado T,Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 1015.
  • 8
    Khan MJ,Castle PE,Lorincz AT,Wacholder S,Sherman M,Scott DR,Rush BB,Glass AG,Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (hpv) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 10729.
  • 9
    Berkhof J,Bulkmans NW,Bleeker MCG,Bulk S,Snijders PJF,Voorhorst FJ,Meijer CJLM. HPV type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev 2006; 15: 126873.
  • 10
    Bulkmans NW,Rozendaal L,Snijders PJ,Voorhorst FJ,Boeke AJ,Zandwijken GR,van Kemenade FJ,Verheijen RH,Groningen K,Boon ME,Keuning HJ,van Ballegooijen M, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004; 110: 94101.
  • 11
    Bulk S,van Kemenade FJ,Rozendaal L,Meijer CJ. The Dutch CISOE—a framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004; 57: 38893.
  • 12
    Solomon D,Davey D,Kurman R,Moriarty A,O'Connor D,Prey M,Raab S,Sherman M,Wilbur D,Wright T,Jr,Young N. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 21149.
  • 13
    Jacobs MV,Snijders PJ,van den Brule AJ,Helmerhorst TJ,Meijer CJ,Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997; 35: 7915.
  • 14
    van den Brule AJ,Pol R,Fransen-Daalmeijer N,Schouls LM,Meijer CJ,Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002; 40: 77987.
  • 15
    Benedet J,Odicino F,Maisonneuve P,Severi G,Creasman W,Shepherd J,Sideri M,Pecorelli S. Carcinoma of the cervix uteri. J Epidemiol Biostat 1998; 3: 534.
  • 16
    Anderson MC. Premalignant and malignant squamous lesions of the cervix. In: FoxH,WellsM,Haines,Taylor, eds. Obstetrical and gynaecological pathology. New York: Chruchill Livingstone, 1995. 2927.
  • 17
    Kulasingam SL,Hughes JP,Kiviat NB,Mao C,Weiss NS,Kuypers JM,Koutsky LA. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002; 288: 174957.
  • 18
    Cuzick J,Clavel C,Petry KU,Meijer CJ,Hoyer H,Ratnam S,Szarewski A,Birembaut P,Kulasingam S,Sasieni P,Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095101.
  • 19
    Elfgren K,Rylander E,Radberg T,Strander B,Strand A,Paajanen K,Sjoberg I,Ryd W,Silins I,Dillner J. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol 2005; 193: 6507.
  • 20
    van Ballegooijen M,Hermens R. Cervical cancer screening in the Netherlands. Eur J Cancer 2000; 36: 22446.
  • 21
    Bulkmans NW,Rozendaal L,Voorhorst FJ,Snijders PJ,Meijer CJ. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br J Cancer 2005; 92: 18002.
  • 22
    Guido R,Schiffman M,Solomon D,Burke L. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus dna-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol 2003; 188: 14015.
  • 23
    Castle PE,Solomon D,Schiffman M,Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005; 97: 106671.
  • 24
    Clavel C,Masure M,Bory JP,Putaud I,Mangeonjean C,Lorenzato M,Nazeyrollas P,Gabriel R,Quereux C,Birembaut P. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001; 84: 161623.
  • 25
    Cuzick J,Beverley E,Ho LTerry G,Sapper H,Mielzynska I,Lorincz A,Chan WK,Krausz T,Soutter P. HPV testing in primary screening of older women. Br J Cancer 1999; 81: 5548.
  • 26
    Ronco G,Segnan N,Giorgi-Rossi P,Zappa M,Casadei GP,Carozzi F,Dalla,Palma P,Del Mistro A,Folicaldi S,Gillio-Tos A,Nardo G, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 76574.
  • 27
    Mayrand MH,Duarte-Franco E,Coutlee F,Rodrigues I,Walter SD,Ratnam S,Franco EL. Randomized controlled trial of human papillomavirus testing versus pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006; 119: 61523.